Transplantation and long-term overall survival in acute myeloid leukaemia
Mené sur 93 patients âgés atteints d'une leucémie myéloïde aiguë (âge médian : 68,5 ans), cet essai multicentrique de phase II évalue l'efficacité, du point de vue de la proportion de patients ayant bénéficié d'une greffe allogénique de cellules souches hématopoïétiques pendant leur première rémission complète, et la toxicité d'un traitement d'induction combinant vénétoclax et décitabine
Two thirds of patients with acute myeloid leukaemia are older than 60 years and have poor long-term survival. Although new front-line therapies, such as venetoclax-based regimens,1,2 CPX-351,3 targeted inhibitors,4,5 and maintenance therapy,6 have improved outcomes in older patients, effective long-term cures remain elusive. Allogeneic haematopoietic stem-cell transplantation (HSCT) has become a more viable option for this patient population as a result of innovations, such as reduced-intensity conditioning, the use of alternative donors, and improved supportive care, which have led to incremental improvements in overall survival.
The Lancet Haematology , commentaire, 2023